<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">23137182</PMID>
      <DateCompleted>
        <Year>2013</Year>
        <Month>05</Month>
        <Day>29</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2013</Year>
        <Month>11</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1744-764X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2013</Year>
              <Month>Jan</Month>
            </PubDate>
          </JournalIssue>
          <Title>Expert opinion on drug safety</Title>
          <ISOAbbreviation>Expert Opin Drug Saf</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Saxagliptin overview: special focus on safety and adverse effects.</ArticleTitle>
        <Pagination>
          <StartPage>103</StartPage>
          <EndPage>109</EndPage>
          <MedlinePgn>103-9</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1517/14740338.2013.741584</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Saxagliptin (see drug summary box) is a glucose-lowering agent that belongs to the class of Dipeptidylpeptidase-4 (DDP-4) inhibitors used in the treatment of T2DM. Clinical efficacy of saxagliptin as single agent as well as in combination with other medications used for the treatment of T2DM has been well established in several randomized trials. Treatment with saxagliptin is effective, generally safe and well tolerated, apart from a small increase in the incidence of infections such as nasopharyngitis. Its use is not associated with increase risk of hypoglycemia and it is weight neutral. Saxagliptin can be used safely in renal failure (with dose adjustment) and in hepatic impairment. When saxagliptin is used in combination with a strong inhibitor of CYP3A4/A5, reduction in the daily dosage is recommended.</AbstractText>
          <AbstractText Label="AREAS COVERED" NlmCategory="METHODS">This paper briefly discusses efficacy and pharmacokinetics of saxagliptin. The paper highlights in detail saxagliptin-associated adverse effects, drug interactions, its use in patients with renal and hepatic disease and long-term safety concerns.</AbstractText>
          <AbstractText Label="EXPERT OPINION" NlmCategory="CONCLUSIONS">Saxagliptin has comparable efficacy with other DPP-4 inhibitors. It is generally safe and well tolerated; however, it requires dose adjustment in renal disease as well as when used with drugs that are strong inhibitor or inducer of CYP3A4/A5 isoforms. Future safety questions regarding immune system and development of cancer still remain to be completely answered.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ali</LastName>
            <ForeName>Shamsa</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Tulane University, Medicine, New Orleans 70112, USA. vfonseca@tulane.edu</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Fonseca</LastName>
            <ForeName>Vivian</ForeName>
            <Initials>V</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Expert Opin Drug Saf</MedlineTA>
        <NlmUniqueID>101163027</NlmUniqueID>
        <ISSNLinking>1474-0338</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9GB927LAJW</RegistryNumber>
          <NameOfSubstance UI="C502994">saxagliptin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PJY633525U</RegistryNumber>
          <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054796" MajorTopicYN="N">Drug Dosage Calculations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007674" MajorTopicYN="N">Kidney Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008107" MajorTopicYN="N">Liver Diseases</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>11</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2013</Year>
          <Month>5</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">23137182</ArticleId>
        <ArticleId IdType="doi">10.1517/14740338.2013.741584</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
